BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Belgium

Trial Profile

BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Belgium

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease; Myocardial infarction; Thrombosis; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms BIOFLOW-III
  • Sponsors BIOTRONIK
  • Most Recent Events

    • 11 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
    • 08 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 08 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top